YU177390A - Postupak za pripremanje aktivne vakcine protiv lajamske bolesti - Google Patents

Postupak za pripremanje aktivne vakcine protiv lajamske bolesti

Info

Publication number
YU177390A
YU177390A YU177390A YU177390A YU177390A YU 177390 A YU177390 A YU 177390A YU 177390 A YU177390 A YU 177390A YU 177390 A YU177390 A YU 177390A YU 177390 A YU177390 A YU 177390A
Authority
YU
Yugoslavia
Prior art keywords
antigen
burgdorferi
lyme disease
vaccine
disease vaccine
Prior art date
Application number
YU177390A
Other languages
English (en)
Other versions
YU48250B (sh
Inventor
M.M. Simon
E.U. Schaible
K. Eichmann
M. Kramer
W. Reinhard
Original Assignee
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.
Deutsches Krebsforschungszentrum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25885304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU177390(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V., Deutsches Krebsforschungszentrum filed Critical Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.
Priority to SI9011773A priority Critical patent/SI9011773B/sl
Publication of YU177390A publication Critical patent/YU177390A/sh
Priority to HR940545A priority patent/HRP940545B1/xx
Publication of YU48250B publication Critical patent/YU48250B/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Cepivo proti lajmski bolezni, postopek za pridobivanje tega cepiva, monoklonsko protitelo, antigen, rekombinantna DNA, rekombinanten vektor in postopek za pridobivanje antigena Izum se nanaša na pasivno cepivo proti lajmski bolezni, ki vsebuje enega ali več monoklonskih protiteles, specifičnih za 31 kD antigen (OspA) ali/in 34 kD antigen (OspB) B. burgdorferi, ter v posksusnih živalih spomanjkljivo imunostjo, ki smo jih inficirali z vitalnimi patogenimi organizmi B. burgdorferi, preprečimo izoblikovanje artritisa, pankarditisa in hapatitisa. Izum se nadalje nanaša tudi na postopek za pridobivanje cepiva v smislu izuma, na hibridomske celične linije ECACC 89 09 1302, ECACC 90050405, ECACC90050406 in ECACC90050407, ki izločajo protitelesa v smislu izuma, ter na patogeni B. burgodorferi soj ZS7 (DSM5527). Prav tako je predmet izuma antigen B. burgdorferi, ki imunsko reagira s protitelesom v smislu izuma, postopek za pridobivanje antigenov v smislu izuma, kot tudi aktivnih cepiv proti lajmski bolezni, ki vsebujejo antigen v smislu izuma kot bistveno sestavino. Izum se nanaša končno na postopek za izolacijo in ponovno in ponovno kultiviranje patogenih B. burgdorferi iz poskusnih živali s pomanjkljivo imunostjo.
YU177390A 1989-09-19 1990-09-18 Postupak za pripremanje aktivne vakcine protiv lajmske bolesti YU48250B (sh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI9011773A SI9011773B (en) 1989-09-19 1990-09-18 Vaccine against lyme disease, process for obtaining it, monoclonal antibody, antigene, recombinant dna, recombinant vector and process for obtaining this antigene
HR940545A HRP940545B1 (en) 1989-09-19 1994-09-15 Vaccine against lyme disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3931236 1989-09-19
DE4015911A DE4015911A1 (de) 1989-09-19 1990-05-17 Impfstoff gegen die lyme-krankheit

Publications (2)

Publication Number Publication Date
YU177390A true YU177390A (sh) 1993-05-28
YU48250B YU48250B (sh) 1997-09-30

Family

ID=25885304

Family Applications (2)

Application Number Title Priority Date Filing Date
YU177390A YU48250B (sh) 1989-09-19 1990-09-18 Postupak za pripremanje aktivne vakcine protiv lajmske bolesti
YU9097A YU49370B (sh) 1989-09-19 1997-03-12 Postupak za pripremanje vakcine protiv lajmske bolesti

Family Applications After (1)

Application Number Title Priority Date Filing Date
YU9097A YU49370B (sh) 1989-09-19 1997-03-12 Postupak za pripremanje vakcine protiv lajmske bolesti

Country Status (24)

Country Link
US (6) US5178859A (sh)
EP (5) EP0861664A3 (sh)
JP (3) JP3205932B2 (sh)
KR (2) KR100205462B1 (sh)
AT (4) ATE175576T1 (sh)
AU (1) AU651560B2 (sh)
CA (1) CA2025597C (sh)
CZ (2) CZ284616B6 (sh)
DE (5) DE4015911A1 (sh)
DK (4) DK0418827T3 (sh)
ES (4) ES2129551T3 (sh)
FI (1) FI102248B (sh)
GR (3) GR3018995T3 (sh)
HK (2) HK1002405A1 (sh)
HR (1) HRP940545B1 (sh)
HU (2) HU212716B (sh)
IE (1) IE903377A1 (sh)
NO (2) NO311767B1 (sh)
NZ (1) NZ235260A (sh)
PL (2) PL169804B1 (sh)
PT (1) PT95349B (sh)
SI (1) SI9011773B (sh)
SK (3) SK283089B6 (sh)
YU (2) YU48250B (sh)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US7094391B1 (en) * 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US5582829A (en) * 1990-04-05 1996-12-10 Rx Technologies, Inc. Sonicated borrelia burgdorferi vaccine
JPH06501382A (ja) 1990-06-15 1994-02-17 エール ユニバーシティ ライム病の予防および診断に用いる組成物および方法
EP1016416A3 (en) * 1990-07-06 2002-10-23 Wyeth Vaccine against lyme disease and a challenge model for evaluating vaccine efficacy
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
US6872550B1 (en) 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
JPH07501687A (ja) * 1991-08-15 1995-02-23 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） ボレリア・ブルグドルフェリのサブグループのｏｓｐ　ａ　蛋白、それをコードしている遺伝子およびワクチン
US6676942B1 (en) * 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
PT100980B (pt) * 1991-10-18 1999-07-30 Connaught Lab Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao
EP0540457A1 (en) * 1991-10-22 1993-05-05 Symbicom Ab Improvements in Borrelia burgdorferi diagnosis and prophylaxis
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
US6716591B1 (en) 1993-07-30 2004-04-06 Yale University B. burgdorferi polypeptides
US5656451A (en) * 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US5558993A (en) * 1994-06-17 1996-09-24 The Regents Of The University Of California Cloned Borrelia burgdorferi virulence protein
GB9511909D0 (en) * 1995-06-12 1995-08-09 Microbiological Res Authority Vaccine
ATE301716T1 (de) 1996-02-21 2005-08-15 Univ Texas Vmp-ähnliche sequenzen von pathogener borrelia
DE19632862B4 (de) 1996-08-14 2006-08-03 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe
US6458555B1 (en) * 1996-08-21 2002-10-01 Gerd Bach Cytologic method of examining mucous membranes
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
DE19740735A1 (de) * 1997-09-16 1999-03-18 Max Planck Gesellschaft Arzneimittel zur Therapie einer manifesten Lyme-Borreliose
US6306623B1 (en) 1998-02-24 2001-10-23 The University Of California Leptospiral major outer membrane protein LipL32
DK1100922T3 (da) 1998-07-31 2008-06-16 Gundersen Lutheran Medical Fou Anvendelser af én eller flere borreliacide epitoper på ydermembranprotein C fra Borrelia burgdorferi (OspC) som vaccine
WO2000056298A2 (en) * 1999-03-19 2000-09-28 Luitpold Pharmaceuticals, Inc. Treatment of lyme disease with polysulfated glycosaminoglycan formulations
AU4800500A (en) 1999-06-21 2001-01-09 Milkhaus Laboratory, Inc. Method for treatment of lyme disease
DK1311540T3 (da) 2000-08-18 2008-04-28 Brookhaven Sciences Ass Llc Ændret OspA af Borrelia Burgdorferi
AU2003299872A1 (en) 2002-12-20 2004-07-22 Board Of Regents, The University Of Texas System Vmp-like sequences of pathogenic borrelia species and strains
KR101192127B1 (ko) 2006-11-03 2012-10-17 쉐링-프라우 리미티드 개 라임병 백신
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP2167536A1 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
WO2011063003A2 (en) * 2009-11-17 2011-05-26 Abaxis, Inc. Peptides and methods for the detection of lyme disease antibodies
US8758772B2 (en) 2011-11-04 2014-06-24 Abaxis, Inc. Peptides and methods for the detection of lyme disease antibodies
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
US9610336B1 (en) * 2014-07-16 2017-04-04 Amiram Katz Immunotherapy for lyme disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4772464A (en) 1985-08-01 1988-09-20 Miles Laboratories, Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4888276A (en) 1986-06-26 1989-12-19 Minnesota Mining And Manufacturing Company Method and composition for the diagnosis of Lyme disease
US4721617A (en) 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
US5034515A (en) * 1987-09-22 1991-07-23 Wisconsin Alumni Research Foundation Staphylococcal fibronectin receptor, monoclonal antibodies thereto and methods of use
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
ATE140461T1 (de) * 1989-12-22 1996-08-15 Mikrogen Molekularbiol Entw Immunologisch aktive proteine von borrelia burgdorferi, zusammenhängende testkits und impfstoff
JPH06501382A (ja) * 1990-06-15 1994-02-17 エール ユニバーシティ ライム病の予防および診断に用いる組成物および方法
EP1016416A3 (en) * 1990-07-06 2002-10-23 Wyeth Vaccine against lyme disease and a challenge model for evaluating vaccine efficacy
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
JPH07501687A (ja) * 1991-08-15 1995-02-23 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） ボレリア・ブルグドルフェリのサブグループのｏｓｐ　ａ　蛋白、それをコードしている遺伝子およびワクチン
DK0642574T3 (da) * 1991-08-27 1999-08-16 Novo Nordisk As Detergentsammensætninger
PT100980B (pt) * 1991-10-18 1999-07-30 Connaught Lab Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao
EP0625052A4 (en) * 1991-10-21 1995-07-19 Medimmune Inc SECRETION SIGNAL OF LIPOPROTEIN-ENCODING DNA CONTAINING BACTERIAL EXPRESSION VECTOR.

Also Published As

Publication number Publication date
EP0861664A2 (de) 1998-09-02
NO20014624D0 (no) 2001-09-24
ES2129551T3 (es) 1999-06-16
HU211228A9 (en) 1995-11-28
DE59010903D1 (de) 2000-05-11
HRP940545A2 (en) 1997-04-30
IE903377A1 (en) 1991-04-10
JPH03209400A (ja) 1991-09-12
KR910005889A (ko) 1991-04-27
PT95349B (pt) 1997-06-30
DE4015911A1 (de) 1991-03-28
DE59010863D1 (de) 1999-02-25
DE59010888D1 (de) 1999-12-23
PL170229B1 (pl) 1996-11-29
NO315905B1 (no) 2003-11-10
JP2001069969A (ja) 2001-03-21
HU905816D0 (en) 1991-03-28
DK0633028T3 (da) 2000-04-10
KR100205462B1 (ko) 1999-07-01
EP0633313A1 (de) 1995-01-11
EP0418827A1 (de) 1991-03-27
IE990173A1 (en) 2000-11-01
ES2145077T3 (es) 2000-07-01
SK283089B6 (sk) 2003-02-04
SK151198A3 (en) 1999-04-13
US6613331B1 (en) 2003-09-02
EP0633313B1 (de) 2000-04-05
SK151098A3 (en) 1999-04-13
HUT59613A (en) 1992-06-29
AU6244490A (en) 1991-03-28
EP0418827B1 (de) 1995-12-20
SK283088B6 (sk) 2003-02-04
NO904062L (no) 1991-03-20
DK0418827T3 (da) 1996-05-06
ES2082812T3 (es) 1996-04-01
YU48250B (sh) 1997-09-30
US5434077A (en) 1995-07-18
CA2025597C (en) 2004-02-03
NO20014624L (no) 1991-03-20
DK0633313T3 (da) 2000-07-24
JP3205932B2 (ja) 2001-09-04
EP0643974B1 (de) 1999-01-13
PT95349A (pt) 1991-05-22
GR3018995T3 (en) 1996-05-31
ATE186646T1 (de) 1999-12-15
JP2001204467A (ja) 2001-07-31
SI9011773A (sl) 1998-04-30
GR3033675T3 (en) 2000-10-31
JP3328644B2 (ja) 2002-09-30
NO904062D0 (no) 1990-09-18
SK456090A3 (en) 1999-11-08
DE59009978D1 (de) 1996-02-01
JP3418171B2 (ja) 2003-06-16
NZ235260A (en) 1993-04-28
AU651560B2 (en) 1994-07-28
US5686267A (en) 1997-11-11
KR100202128B1 (en) 1999-06-15
US5178859A (en) 1993-01-12
FI102248B1 (fi) 1998-11-13
SI9011773B (en) 2001-12-31
ES2141182T3 (es) 2000-03-16
CZ284538B6 (cs) 1998-12-16
DK0643974T3 (da) 1999-09-06
FI102248B (fi) 1998-11-13
FI904597A0 (fi) 1990-09-18
CZ284616B6 (cs) 1999-01-13
GR3032010T3 (en) 2000-03-31
ATE131732T1 (de) 1996-01-15
PL169804B1 (pl) 1996-09-30
ATE175576T1 (de) 1999-01-15
HU212716B (en) 1996-10-28
CZ456090A3 (cs) 1998-08-12
ATE191499T1 (de) 2000-04-15
HRP940545B1 (en) 2000-06-30
EP0861664A3 (de) 1999-02-24
EP0643974A1 (de) 1995-03-22
HK1002405A1 (en) 1998-08-21
US5856447A (en) 1999-01-05
EP0633028B1 (de) 1999-11-17
SK280285B6 (sk) 1999-11-08
EP0633028A1 (de) 1995-01-11
NO311767B1 (no) 2002-01-21
CA2025597A1 (en) 1991-03-20
CZ97095A3 (en) 1995-09-13
US5780030A (en) 1998-07-14
HK1013620A1 (en) 1999-09-03
YU49370B (sh) 2005-09-19
YU9097A (sh) 1999-06-15

Similar Documents

Publication Publication Date Title
YU177390A (sh) Postupak za pripremanje aktivne vakcine protiv lajamske bolesti
ATE211654T1 (de) Antigene des hybriden m-proteins und träger für gruppe a streptokokkenimpfstoff
DK0612250T3 (da) Fremgangsmåder og præparater med relation til nyttige Moraxella catarrhalis-antigener
DE69534354D1 (de) CHIMÄRE cDNA-KLONE DES VIRUS DER INFEKTIÖSEN BURSAL-KRANKHEIT, EXPRESSIONSPRODUKTE UND DARAUF BASIERENDE IMPFSTOFFE
PL304419A1 (en) Urease based vaccine against heliobacter infections
HUT50048A (en) Process for producing streptococcus protein antigen and pharmaceutical compositions comprising same
ES8500997A1 (es) Un metodo para producir un peptido.
BR0016567A (pt) Composições e vacinas contendo antìgeno(s) de cryptosporidium parvum e de outro patógeno entérico
ATE196425T1 (de) Impfstoff gegen die lyme-krankheit
MX9203629A (es) Composiciones de anticuerpos monoclonales para el tratamiento profilactico o terapeutico de infecciones bacterianas debidas a estreptococos del grupo b.
Dua et al. Studies on Pasteurella multocida. VI. Nature of systemic immunity and analysis of the correlation between levels of immunity induced by various fowl cholera vaccines and protection against challenge
DE69737323D1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
Wilson Immunological aspects of bovine trypanosomiasis: III. Patterns in the development of immunity
Ramezanalizadeh et al. Evaluation of hyperimmune colostrum production in bovine against cariogenic streptococci and its impact on growth and bacterial biofilm formation
EP0107845A3 (en) Vaccine for immunizing cattle against infectious bovine keratoconjunctivitis by moraxella bovis
Jones et al. The effect of syringe and cyclical passage on antigenic variants of Trypanosoma vivax
Surján et al. Long-term cultivation of lymph node fragments and cells of hyperimmunized rabbits
Shifrine et al. Infection of cattle with Mycoplasma mycoides by nasal instillation
GR3020495T3 (en) Two-phase system for the production and presentation of foreign antigens in hybrid live vaccines
Fuenzalida et al. Production of hyperimmune antirabies serum in horses
Pacheo Preparation of a national standard of lyophilized tetanus antitoxin.
Hoare et al. Comparison of selected protocols for the generation of IgA isotype monoclonal antibodies against the gut parasite, Eimeria tenella
SU1676629A1 (ru) Способ иммунизации животных
Tlaskalová-Hogenová et al. DEVELOPMENT OF IgA RESPONSES IN GERMFREE PIGLETS AFTER LOCAL
Micalizzi et al. Protective Activity of Different Immunosera AgainstClostridium chauvoei